Evidence map›Paper›PMID 42277046›Full record

ArticleNature communications2026

Oligoclonal expansion of atypical Vδ2

Esther Bandala-Sanchez, Laura Scolamiero, Josh Chatelier, Kerry A Ramsay, Alison Morey, Sylvia Tsang, Maureen Forde, Julian J Bosco, Marsus Pumar, Silvia Sanchez-Ramon and 7 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Esther Bandala-SanchezWalter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Laura ScolamieroDepartment of Clinical Immunology & Allergy, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Josh ChatelierDepartment of Clinical Immunology & Allergy, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Kerry A RamsayWalter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Alison MoreyDepartment of Microbiology & Immunology, The University of Melbourne, at The Peter Doherty Institute of Infection and Immunity, Melbourne, VIC, Australia.
Sylvia TsangWalter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Maureen FordeWalter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Julian J BoscoAllergy, Asthma and Clinical Immunology Service, Alfred Health, Melbourne, VIC, Australia.
Marsus PumarDepartment of Allergy & Immunology, Monash Health, Melbourne, VIC, Australia.
Silvia Sanchez-RamonDepartment of Clinical Immunology, Instituto de Medicina de Laboratorio and Health Research Institute of the Hospital Clínico San Carlos, Madrid, Spain.
Kissy Guevara-HoyerDepartment of Clinical Immunology, Instituto de Medicina de Laboratorio and Health Research Institute of the Hospital Clínico San Carlos, Madrid, Spain.ORCID http://orcid.org/0000-0003-3568-8821
Jesús Fuentes-AntrásNEXT Oncology, Hospital Universitario Quirónsalud Madrid, Madrid, Spain.
Jack GodsellDepartment of Clinical Immunology & Allergy, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Kymble SpriggsDepartment of Clinical Immunology & Allergy, Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-5302-0334
Anouk von BorstelDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Samantha ChanWalter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-3785-7759
Lauren J HowsonWalter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. howson.l@wehi.edu.au.ORCID http://orcid.org/0000-0003-3522-4533

Funding

cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Department of Health | National Health and Medical Research Council (NHMRC) 2007884NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIDA NIH HHS 75N95020D00005NIH HHS 75N93023D00005NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Good's syndrome is a rare adult-onset immunodeficiency characterized by thymoma, hypogammaglobulinemia, B-cell lymphopenia, and T-cell dysfunction. Despite well-characterized defects in conventional immune subsets, the impact of this disorder on unconventional T cells, including γδ T cells, remains largely unexplored. In this study, we analyse γδ T cells in 10 patients with Good's syndrome using immunophenotyping, functional assays, and T-cell receptor (TCR)δ repertoire profiling of peripheral blood and thymoma tissue. Our analyses reveal a pronounced expansion of the Vδ2⁻ γδ T-cell compartment, composed primarily of Vδ1⁺, Vδ3⁺ and the exceptionally rare Vδ8⁺ subsets. The Vδ2⁻ cells are characterized by an activated and effector phenotype and a private and oligoclonal TCRδ repertoire. The thymoma tissue contains distinct clonotypes compared to circulation, suggesting clonal focusing in response to the tumor. Together, our findings show that γδ T-cell perturbations are integral characteristics of Good's syndrome and broaden our understanding of immune dysregulation in this acquired immunodeficiency.

Indexed as

AgammaglobulinemiaImmunologic Deficiency SyndromesReceptors, Antigen, T-Cell, gamma-deltaThymomaT-LymphocytesT-Lymphocyte SubsetsAdultFemaleHumansImmunophenotypingLymphopeniaMaleMiddle AgedThymus NeoplasmsReceptors, Antigen, T-Cell, gamma-delta

Identifiers

PMID42277046
PMCPMC13407883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.